Merck acquires US cancer specialist Springworks
DARMSTADT (dpa-AFX) - As expected, the Darmstadt-based Merck Group is acquiring the US cancer specialist SpringWorks Therapeutics . Merck is paying $47 per SpringWorks share. This values the company at three billion euros, as Merck announced on Monday. The acquisition will be financed from existing cash and new debt. The purchase is expected to close in the second half of 2025. SpringWorks shareholders and the authorities must first approve the deal. For Merck, this is the largest acquisition in years. Last week, the DAX -listed company reported "advanced discussions."
Springworks contributes directly to the Merck Group's sales, the statement added. Merck expects a positive effect on earnings per share in fiscal year 2027. Furthermore, with the acquisition, Merck is expanding both its Healthcare division and its presence in the US. Following this acquisition, Merck remains in a position to handle further larger transactions, said CEO Belén Garijo in a statement: "Beyond this intended transaction, we will continue to explore opportunities for suitable acquisitions in our three complementary business sectors."/niw/stk
On my own behalf
By the way: US stocks are even tradable at finanzen.net ZERO until 11 p.m. (no order fees, plus spreads). Open a free account now and receive a free share as a gift.
Knock-outs allow speculative investors to participate disproportionately in price movements. Simply select the desired leverage, and we'll show you suitable open-end products on Merck.
The lever must be between 2 and 20
finanzen.net
